Dopamine antagonist binding increases in two behaviorally distinct striatal denervation syndromes.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001519:Behavior / Q000502:physiology*; D002090:Butyrophenones / Q000378:metabolism*; D003342:Corpus Striatum / Q000187:drug effects / Q000502:physiology*; D003714:Denervation; D006220:Haloperidol / Q000378:metabolism*; D006801:Humans; D006892:Hydroxydopamines / Q000494:pharmacology; D008297:Male; D009434:Neural Pathways / Q000502:physiology; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism*; D013134:Spiperone / Q000378:metabolism*; D013239:Stereotyped Behavior / Q000187:drug effects / Q000502:physiology*; D013378:Substantia Nigra / Q000187:drug effects / Q000502:physiology*
D002090:Butyrophenones; D006892:Hydroxydopamines; D011954:Receptors, Dopamine; D013134:Spiperone; D006220:Haloperidol; D001058:Apomorphine